Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Momentum
Regeneron Pharmaceuticals (REGN) has drawn investor attention after its recent share price move, with the stock closing at $776.31. That shift is prompting fresh interest in how its fundamentals stack up today.
See our latest analysis for Regeneron Pharmaceuticals.
The recent 1 month share price return of 8.07% and 3 month share price return of 33.10% suggest momentum has been building, while a 1 year total shareholder return of 8.98% points to steadier progress over a longer stretch.
If Regeneron has you looking more closely at healthcare, this could be a good moment to scan healthcare stocks for other names showing solid longer term performance profiles.
With Regeneron trading at $776.31 and an intrinsic value estimate implying roughly a 54% gap, along with annual revenue of US$14.25b and net income of US$4.58b, is the market leaving upside on the table or already pricing in future growth?
Most Popular Narrative: 60% Undervalued
At a last close of $776.31 versus a narrative fair value near $781, the current setup is framed as materially undervalued with modest upside implied.
Regeneron's broad and advancing pipeline including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity positions the company to benefit from demographic driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline driven earnings upside.
Curious what kind of revenue build, margin profile, and future P/E multiple are baked into that fair value line? The narrative leans on steady expansion, disciplined profitability assumptions, and a higher earnings multiple than today. The exact mix of growth, margins, and discount rate is where the story really gets interesting.
Result: Fair Value of $781.13 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story could shift quickly if EYLEA headwinds intensify or if regulators delay key EYLEA HD and pipeline approvals that underpin the current upside case.
Find out about the key risks to this Regeneron Pharmaceuticals narrative.
Build Your Own Regeneron Pharmaceuticals Narrative
If you see the story differently or prefer to stress test the assumptions yourself, you can create your own view in minutes: Do it your way.
A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Regeneron Pharmaceuticals.
Looking for more investment ideas?
If Regeneron is on your radar, do not stop there. Broaden your watchlist with other angles the market might be overlooking right now.
- Spot potential value opportunities early by scanning these 875 undervalued stocks based on cash flows that may be pricing in more caution than their underlying cash flows suggest.
- Explore fast growing themes by checking out these 25 AI penny stocks that are tied to real business models rather than just buzz.
- Strengthen your income focus by reviewing these 14 dividend stocks with yields > 3% that already offer yields above 3% and may help balance more growth orientated holdings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com